Stock Track | Eli Lilly Soars 10.12% Intraday on Strong Q4 Earnings Beat and Upbeat 2026 Guidance for Weight-Loss Drugs

Stock Track
02/04

Eli Lilly's stock surged 10.12% during intraday trading on Wednesday, marking a significant upward movement for the pharmaceutical giant.

The sharp rise follows the company's release of fourth-quarter 2025 financial results that substantially exceeded analyst expectations, with adjusted earnings per share of $7.54 beating estimates of $6.67 and revenue of $19.29 billion surpassing the $17.96 billion consensus.

Investors responded enthusiastically to Eli Lilly's optimistic 2026 guidance, which projects adjusted EPS of $33.50 to $35.00 and revenue of $80 billion to $83 billion, both above market forecasts, driven by soaring demand for weight-loss medications Zepbound and Mounjaro.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10